Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2024; 15(3): 530-551
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.530
Potential application of Nardostachyos Radix et Rhizoma-Rhubarb for the treatment of diabetic kidney disease based on network pharmacology and cell culture experimental verification
Meng-Ying Che, Ling Yuan, Jiao Min, Duo-Jie Xu, Dou-Dou Lu, Wen-Jing Liu, Kai-Li Wang, Yan-Yan Wang, Yi Nan
Meng-Ying Che, Jiao Min, Wen-Jing Liu, Yi Nan, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Ling Yuan, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Duo-Jie Xu, Kai-Li Wang, Traditional Chinese Medicine College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Dou-Dou Lu, School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Yan-Yan Wang, Department of Endocrinology, Yinchuan Hospital of Traditional Chinese Medicine, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Author contributions: Che MY conducted most of the experiments, analyzed the data, completed the figure production, and wrote the manuscript; Min J carried out a portion of the experiments and participated in the production of the figures and the composition of the manuscript; Xu DJ and Liu WJ carried out part of the experiments and participated in the statistical analysis of the data; Lu DD and Wang KL performed the network pharmacology prediction; Yuan L and Wang YY designed the study; Nan Y revised and improved the manuscript; all authors approved the final version of the article.
Supported by National Natural Science Foundation of China, No. 81573695, No. 81860894, and No. 81674096; and Ningxia Key Research and Development Plan Project, No. 2021BEG03106.
Institutional review board statement: The study did not involve human or animal experiments.
Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi Nan, MD, Professor, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080011@nxmu.edu.cn
Received: November 2, 2023
Peer-review started: November 2, 2023
First decision: November 21, 2023
Revised: December 5, 2023
Accepted: January 18, 2024
Article in press: January 18, 2024
Published online: March 15, 2024
Processing time: 134 Days and 9 Hours
Core Tip

Core Tip: The Nardostachyos Radix et Rhizoma-rhubarb drug pair may upregulate BCL-2 and STAT3 protein expression, and downregulate BAX, Caspase3, and Caspase9 protein expression, thus activating the advanced glycation end products (AGEs)-receptor for AGEs signaling pathway, inhibiting the vitality of TCMK-1 cells, reducing their apoptosis, and arresting them in the G0/G1 phase to protect them from damage by high glucose.